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Abstract: China is expected to become one of the largest markets for prescription drugs 
in the world and pharmaceutical advertising is becoming increasingly important, 
particularly in the highly socially and culturally contested area of mental health. This 
article briefly explores the background of drug advertising policies in China and the 
UK and focuses on the distinctive challenges of antidepressant drug regulation. Then, 
using tools of Critical Discourse Analysis, it examines Chinese antidepressants adverts, 
and compares them with relevant British adverts. The findings indicate that, relative to 
the UK, Chinese antidepressant adverts are generally oversimplified, and the critical 
information concerning the concepts of caution, danger and adverse effects are 
underrepresented. However, there are many interdependent factors that contribute to 
the distinctive Chinese antidepressant drug regulatory regime. Hence, Chinese policy 
makers must maintain a delicate balance between learning from Western regulatory 
regimes, but also avoiding borrowing too heavily from them. 
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With the growing array of mediations and their availability on the internet, drug 
advertising and its regulation is becoming increasingly important to individuals and 
societies and is widely discussed in the fields of discourse analysis3, policy studies4 and 
social research5. Drug advertising blends health, scientific and commercial information, 
and the representation of drug advertising is largely shaped by a wide range of factors 
from the institutional and social levels. Drug advertising is also a major economic 
activity. Global pharmaceutical companies spend between 24 per cent and 33 per cent 
of total sales revenue on marketing, advertising and promotional activities, about twice 
as much as on research and development6. They are also important political actors on 
the local, national and international levels.   
 
The Chinese case is particularly interesting and important since the Chinese health 
system has recently gone through a number of huge transformations since the 1980s. 
Moreover, the changing and contested role of drugs and drug advertising (particularly 
in relation to mental health) in China makes it potentially one of the largest and most 
contested markets for prescription drugs (and antidepressants) in the world. At present, 
direct-to-consumer-advertising for prescription drugs (DTCA-PD) is illegal in China. 
However, with the growth of globalization and the internet, access to drug advertising 
is becoming increasingly difficult to control.  
 
In this article, the focus is on the Chinese case. However, in order to understand its 
relative distinctiveness we will be comparing it to the UK case. The UK was chosen 
because it has a key similarity to the Chinese context – in both cases prescription drug 
advertising is illegal except in recognized medical journals (hence ruling out a China-
USA comparison). It also has an important difference – the UK has a relatively lengthy 
history of both antidepressant usage and advertising regulation whereas China has 
limited experience of both. Using tools from critical discourse analysis to explore the 
                                                          
3 Glinert 2005; Jones, Greenfield and Bradley 1999. 
4 Geyer 2011; Stryer and Bero 1996; Lee et al. 1991. 
5 Cohen et al. 2001; Lövdahl, Riska and Riska 1999. 
6 House of Commons 2005. 
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linguistic and discursive patterns of antidepressant advertisements in Chinese and UK 
medical journals, we will examine how linguistic patterns in anti-depressant drug 
advertising in China and the UK have evolved in recent times and explore some of the 
wider policy contexts that have shaped these developments. The research concludes by 
exploring: what elements are central in the development of the drug advertising policies 
in China and what are the key implications for both academics and policy actors in 
understanding governance and policy making in this area?    
 
2. Theoretical framework 
 
Though grounded in Complexity Theory7 and its overlapping relationship with Critical 
Discourse Analysis8, the theoretical framework of this article is located in Critical 
Discourse Analysis (CDA) and its implications for policy learning and transfer. CDA 
aims “to show how semiotic, including linguistic, properties of the text connect with 
what is going on socially in the interaction”9. What is essential for CDA, then, is to 
analyze structures of language use, and to systematically relate them to structures of the 
sociocultural context of language use. From this sense, CDA goes beyond linguistic 
analysis, and “seeks to locate discourse within a social world of conflict and 
inequality”10, looking at common concerns shared by social theory and sociolinguistics 
and contributing to explain the interaction between social structures and language use.  
 
CDA has been recently applied to policy studies in the areas of educational policy11, 
public housing policy12, urban policy research13, adult literacy policy14 and a range of 
other areas. CDA is distinct from other approaches in policy studies in the standing 
                                                          
7 Core works of complexity theory and policy include: Byrne and Callaghan 2013; Coveney and Highfield 1995; 
Geyer and Rihani 2010; Geyer and Cairney 2015; Mainzer 1997. 
8 Key works on the relationship between complexity and critical discourse analysis include: Cameron and Larsen-
Freeman 2007; Larsen-Freeman 1997, Larsen-Freeman and Cameron 2008. 
9 Fairclough 2001, 240. 
10 Sealey and Carter, 2004, 58. 
11 Falk 1994; Luke 1997. 
12 Marston 2000. 
13 Jacob 2006. 
14 Hamilton 2014. 
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which it gives to language analysis – analysis of ‘texts’ in a comprehensive sense – 
within discourse analysis. As Fairclough argues, in policy-making and policy debate, 
there is a focal relationship between problem and solution; CDA, although does not aim 
to find such solutions, can contribute to developing models for analysing them that 
accentuate this relationship.”15 Hence, the work of this article is to explore the features 
of language-using in Chinese antidepressant advertisements and connect them with the 
multiple levels of discursive events and policy-related socioeconomic contexts that give 
rise to such language use.  
 
Given the inherent complexity and subtlety of multi-level, political-linguistic policy 
making, we intend to question traditional implications of policy learning and transfer. 
There is a very lengthy history within different fields of policy studies regarding the 
importance and implications of policy learning and transfer between different countries 
and policy contexts. For example, post WW2 modernization theory promoted the 
simplistic belief that fundamentally all developing countries had to do in order to 
develop was to copy, as closely as possible, the policy strategies of developed nations 
and they would automatically develop. This was followed in the 1970s and 1980s by 
the emphasis of the World Bank/IMF on a common ‘structural adjustment framework’ 
for all developing countries.16 Again, the implication was that Western policies were 
more advance and that imitating their policy structures and strategies was the quickest 
road to success. More subtle concepts of ‘policy learning and transfer’ and ‘governance’ 
instead of ‘government’ emerged in the 1990s and 2000s which recognized the highly 
contextual nature of policy making and limits of direct policy learning and transfer.17 
However, they were countered by the narratives of ‘new public management’ and 
‘evidence based policy making’ which often reasserted the dominance of traditional 
forms of Western policy-making.18   
 
                                                          
15 Fairclough 2013, 183. 
16 Easterly 2006, George 1994; Rihani 2002. 
17 Dolowitz and Marsh 2000; Benson and Jordan 2011. 
18 Ansell and Geyer 2017; Cairney 2015; Geyer 2012. 
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In this article, we do not have the space to explore these debates in detail. Nevertheless, 
our comparative discourse analysis of the Chinese and UK policies shines a distinctive 
light on the importance of policy learning/transfer and at the same time, the inherent 
limits and difficulties of such learning and the need to continually critically evaluate 
and assess it.  
 
3. A brief background of prescription drug advertising regulations in the UK 
 
In the UK, the control of medicines advertising was originally based on self-regulation19. 
However, direct to consumer advertising for prescription drugs (DTCA-PD) was very 
limited and made illegal by the March 1992 EU Directive on the advertising of medical 
products for human use (Directive 92/28/EEC) which prohibited DTCA-PD within the 
European Union.20  As early as 1958, guidance for advertising to medical practitioners 
was provided by the Association of British Pharmaceutical Industry (ABPI). In 1974 
the ABPI begun to provide the guidelines that resulted in the current form of 
prescription drugs adverts and the most updated version was published in 2016 (ABPI, 
2016). These guidelines largely conform with the requirements of prescription drugs 
adverts to medical practitioners recommended by the Ethical Criteria for Medicinal 
Drug Promotion developed by the World Health Organisation (WHO, 1988), both 
indicate that information related to names of medicine (both generic and brand), active 
ingredients, dosage, side-effects, precautions, major interactions, etc. In addition, a 
separate body, the Prescription Medicines Code of Practice Authority (PMCPA)21 , 
operates a Code of Practice for the pharmaceutical industry independently of the ABPI.  
 
Hence, the UK has had a highly regulated environment for prescription drug advertising 
to medical practitioners for over 30 years and conforms with WHO standards. This is 
confirmed in a study by Lexchin22 (2010) who notes that although medical journals 
                                                          
19 Green, Haddad and Aronson 2018, 1670. 
20 Geyer 2011 
21 PMCPA 2018. 
22 Lexchin 2010. 
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from developed countries contain the information suggested by the ethical criteria 
developed by the WHO (1988), the safety information is systematically ignored in 
developing countries. As we will explore, less developed regulatory systems and 
sociocultural issues surrounding mental health conditions may play an important role 
in shaping the current forms of antidepressant adverts to medical practitioners.  
 
4. The Sociocultural context of mental depression and the transformation of 
anti-depressant drug advertising policy in China 
 
4.1 Sociocultural context of mental depression and the rise of marketisation of 
antidepressants in China 
 
In China, one central concept of Chinese culture and medicine appears to be the天人相
应 (tian ren xiang ying, ‘correspondence between microcosm and macrocosm')23. This 
means that health is maintained when there is a balanced and harmonious relationship 
between the human body and the environment.  Mental depression can be traced back 
to the concept of 郁症 (yu zheng, ‘stagnation syndrome’) in traditional Chinese 
medicine, which explains it as an imbalance of different elements in the human body24. 
The treatment of such a condition, therefore, often relies on the improvement of the 
social environment or the balance of different elements in the human body. Kleinman25 
pointed out the overwhelmingly social foundations of mental illnesses in Chinese 
society and, in his later work, argued that “attributions of illness onset to social sources, 
the symbolic linking of symptoms to life context, and the alleviation of distress with 
improvement in circumstances point to the sociosomatic mediation of sickness”26.  
 
Therefore, the use of antidepressants has been marginalised in Chinese society for much 
of the 20th century and there is still strong resistance to biomedical treatments for mental 
                                                          
23 Lin 1980, 96. 
24 Ng, Chan, Ho, Wong and Ho 2006. 
25 Kleinman 1982.  
26 Kleinman1992, 546. 
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and emotional disorders. Baum27 examined the tension between legislative change (at 
the level of the state) and phenomenological consistency (at the level of the society and 
individual) surrounding mental health problems in early 1920s in China, and concluded 
that to many contemporary Chinese minds, the theoretical underpinnings of 
biomedicine and scientific psychiatry were inscrutably foreign, improbable, and useless 
in their approach to psychobiological disorder28. A relevant point here is that the side-
effects of biomedicines have not been generally acceptable for Chinese people, who 
had long-established tradition of using natural herbal medicine. As we will argue later, 
this may be connected with the omission of information related to adverse effects in 
Chinese antidepressant adverts.  
 
However, a significant change in the Chinese discussion of depression and the use of 
antidepressants has taken place in the last ten years. Wang29 conducted a longitudinal 
study examining the discussions about mental depression in British and Chinese 
newspapers in the last three decades, finding that Chinese people still frame the 
discussion of mental depression with traditional Chinese concepts, but the depiction of 
depression as a chemical condition started to appear in a significant number of Chinese 
articles since 2009 30 . At the same time, rising health care needs combined with 
pharmaceutical industry development has led to a large-scale market expansion of 
antidepressants. Sales of antidepressants have risen from 25.1 to 56.74 billion RMB in 
the last five years, and are estimated to exceed 60 billion RMB in 201731. This mixture 
has led to a re-conceptualisation that differs in important ways from the Western 
concept. Therefore, it is important to look into the ways in which antidepressants were 
advertised and how the language reflected the sociocultural context.  
 
The next section briefly discusses the policy-related socioeconomic contexts of 
                                                          
27 Baum 2013. 
28 Ibid 4. 
29 Wang 2013. 
30 Ibid 280 
31 Jin 2016. 
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antidepressants advertising, including the upheaval of Chinese healthcare system and 
China’s prescription drug advertising regulatory background, its current status and 
challenges. This will not only contribute to unravelling the interaction between 
language use in antidepressant adverts and the related policy practices, but will provide 
more insight into comparative policy learning and transfer.   
 
4.2 The background of drug advertising policies in China 
In the past 30 years China has gone through huge changes in its health policy and 
systems. During the 1960s and 70s, China’s health system was prevention oriented, 
public health based, and people-centered using local ‘barefoot doctors’. At that time, it 
was praised by the World Health Organization for its successful vaccination 
programmes, elimination of malaria, improving mortality rates for under 5’s, 
elimination of opium usage, and a range of other basic health achievements. Key 
changes occurred following the transition to a more market-oriented approach to 
development in the early to mid-1990s. Under the new system, state funded health care 
was replaced with care funded by a mix of local government, employer and individual 
contributions and private provision of health care was promoted. At the time of huge 
economic upheaval this led to a range of problems including: huge regional variation 
and growing inequality of access to care, growing business orientation and loss of 
public health-oriented culture of the profession32, and poor regulation and corruption. 
By the mid-2000s, the WHO, World Bank and even the Economist criticized China for 
pushing the health market too far/fast33 . In response, in 2007 President Hu iintao 
announced a major health reform to increase funding, make the system more patient-
centered and strengthen its public orientation. However, problems persist in relation to 
growing costs, huge variation in outcomes and access and hidden corruption. 
 
In relation to prescription drug advertising, early regulation from 1978-1993 made no 
distinction between prescription and non-prescription drugs. However, from 1994 
                                                          
32 Zhan 2011. 
33 Ibid. 
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onwards the state authorities defined advertising and separated prescription and non-
prescription drugs. The main regulations concerning the pharmaceutical advertising in 
China are the Advertising Law (promulgated in 1995 and amended in 2015), the Law 
for the Administration of Pharmaceuticals (adopted in 2002), the Standards for the 
Examination and Publication of Drug Advertisements (effective from May 1, 2007 and 
is now under revision), and the Measures for the Examination of Drug Advertisements 
(effective from May 1, 2007). The latest Advertisement Law of the People's Republic 
of China (2015), amended and revised by the Standing Committee of the National 
People’s Congress (NPC) and State Administration for Industry & Commerce (SAIC)34, 
strengthened the inclusion of the critical information about drugs and reaffirmed the 
ban on prescription drug advertising (except in professional journals): 
 
 Article 16: Drug and device advertisements must clearly state critical 
information about the products, such as contraindication and adverse effects; 
Drug and device advertisements must not contain absolute assurances or 
guarantees of the product’s safety.   
 Article 19: Mass media (including broadcasting, television and the internet) 
cannot feature drug, device, health supplement and medical service 
advertisements in disguised forms, such as in news reports or health-related 
public education programs, so as to circumvent being regulated as 
advertisements. 
 
4.3 China’s prescription drug advertising regulatory challenges 
Ma and Lou35 pointed out that although the Chinese government oversees prescription 
drug advertisements and relies on strict pre-approval requirements, compared to the 
huge sums spent on drug promotion, government resources are limited to regulate and 
enforce. Bai36 notes that approval authorities of prescription drug advertising in China 
                                                          
34 Standing Committee of the NPC and SAIC 2015. 
35 Ma and Lou 2014. 
36 Bai 2015. 
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are only regularly trained to understand relevant policies and regulations and to improve 
their implementation competence, without being provided sufficient, efficient and 
reliable drug information. Thirdly, China now operates an Essential Drugs List (EDL), 
a list of core medicines that are reimbursable under Basic Medical Insurance at the 
national and provincial level. The importance of the EDL weakens the role of drug 
advertising strategies for those drugs on the list since manufacturers can be guaranteed 
a significant market share37. However, it also pushes those producers who are not on 
the list to use unbalanced and untruthful advertising to increase market share. 
 
5. A Critical Discourse Analysis of antidepressant advertisements in China 
 
Chinese drug advertising polices state that prescription drugs are only allowed to be 
advertised in officially-approved medical journals. This research looks at all the 
antidepressant advertisements published in China’s leading journal in relation to 
psychiatric illness: The Chinese Journal of Psychiatry - from 1996, when the journal 
was founded, to 2015. This journal was a quarterly publication from 1996 to 2011, and 
became a bi-monthly from 2012. The following chart shows the total number of 
advertisements in each year of the journal:   
 
Table 1: The number of antidepressant advertisements in The Chinese Journal of 
               Psychiatry from 1996 to 2015 
 
        
                                                          









number of Chinese adverts
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As this table shows, the number of advertisements in this medical journal has increased 
significantly over the last 20 years. From 1996 to 2003, the number rose steadily, 
despite a slight fall in 2001. 2004 saw rapid growth with the total number of 
advertisements almost doubled from 2003. This is because in 2003, the Chinese 
government started to increase investment in the public health system due to the SARS 
crisis. As a result, the prescription drugs market began to be more active. 2005 saw a 
slight decrease in the frequency of the advertisements, but subsequently the number of 
advertisements kept increasing until 2008, when the frequency spiked. The dip between 
2012 and 2014 is related primarily to editorial changes in The Chinese Journal of 
Psychiatry.  
 
The following table provides details of the top ten most frequently advertised 
antidepressants in The Chinese Journal of Psychiatry: 
 
Table 2: The top ten most frequently advertised antidepressants in The Chinese 
              Journal of Psychiatry from 1996 to 2015 
 







1 Bo Le Xin Venlofaxine 
Hydrochloride 
54 11 2003-2015 Chengdu Kanghong 
2 Seroxat Paroxtine 50 10 1996-2013 Tianjin 
SmithKline & 
French Lab 
3 Cymbalta Duluoxetine 
Hydrochloride 
43 7 2007-2015 Eli Lilly 
4 Effexor XR Venlofaxine 
Hydrochloride 
34 10 2001-2010 Wyeth 
5 Rui Mei Long Mirtazapine 31 7 2008-2014 N.V.Organon 
6 Cipramil Citalopram 
Hydrobomide 
24 4 2003-2009 Xi’an ianssen 
7 Yan Suan Liu 
Li Da Qin 
Thioridazine 
hydrochloride 
21 3 1996-2001 Hunan Dongting 
8 Zoloft Sertraline 20 3 1998-2008 Pfizer 
8 Lexpro Escitablopram 20 6 2007-2011 Xi’an ianssen 
9 Mi Er Ning Mirtazapine 18 4 2008-2015 Ha’erbin San Lian 
10 Bai Luo Te Escitablopram 17 4 2010-2013 Sichuan Kelun 
 
As this table shows, there are 4 Chinese brands manufactured by Chinese companies 
and 3 Western brands manufactured by Chinese-Western joint ventures. The remaining 
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3 are Western brands produced by Western companies. In this article, we will be making 
a brief comparison with UK anti-depressant drug advertising and examine the 
differences between British and Chinese adverts in the context of their respective 
prescription drug advertising policies. 
 
5.1 A content analysis of Chinese antidepressant advertisements 
Our content analysis is focused on all 6738 advertisements published in The Chinese 
Journal of Psychiatry from 1996 to 2015. To highlight the distinctive features of 
Chinese antidepressant advertisements, the equivalent British version is considered for 
comparison. A brief review of the British version shows clearly that all the adverts have 
very similar structure, covering almost all the categories shown in medical instructions. 
Therefore, only five British adverts randomly chosen from the British Journal of 
Psychiatry from 1996 to 2015 are included for this comparative analysis. The following 
table shows the average coverage percentages across all categories of information in 
Chinese and British adverts:  
 
Table 3: The percentage of information categories covered by Chinese and 
               British advertisements 
 
One quickly sees that around 89 per cent of the advertisements in The Chinese Journal 
of Psychiatry include the use of antidepressants. Around two-thirds cover the dosage 
                                                          
38 The total number of antidepressant advertisements in The Chinese Journal of Psychiatry from 1996 to 2015 is 
424, but as many advertisements for the same brand of antidepressant are repeated between 2 and 7 times in 
different editions of the journal, only the version that appeared for the first time is included for analysis in this 
section.  
Categories of product information Chinese adverts British adverts 
1. Use 89.55% 100.00% 
2. Dosage and Administration 67.16% 100.00% 
3. Contraindication 56.72% 100.00% 
4. Precaution 11.94% 100.00% 
5. Drug interaction 10.45% 100.00% 
6. Adverse effects 37.31% 100.00% 
7. Overdosing 4.48% 40.00% 
8. Presentation 23.88% 100.00% 
9. Price information 11.28% 80.00% 
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and contraindication categories, while precaution and drug interaction are under-
represented. Meanwhile, adverse effects of antidepressants are clearly indicated in 
around 37 per cent of the Chinese adverts. British adverts cover all the above-mentioned 
six categories of information, without exceptions. Presentation is not frequently 
mentioned in Chinese adverts, but is consistently provided in the British ones. The over-
dosage category is covered by 40 per cent of the British adverts, and NHS basic price 
information appears in 80 per cent of the British adverts. In Chinese adverts, only 
around 4 per cent include information related to over-dosage and 11 per cent indicate 
the price of products.  
 
Based on a manual calculation, the average number of the categories that these 67 
Chinese adverts cover is 3.57. This indicates that the information Chinese 
antidepressants adverts provide is neither complete nor balanced (with the precaution, 
drug interaction and overdosage underrepresented). Furthermore, a brief look into the 
content of Chinese antidepressant adverts indicates that the medical information is 
oversimplified relative to the UK. We separated all the adverts based on different 
categories listed in table 3 and compared the average word count in each category in 
the Chinese and British adverts. The following chart shows the result:  
 
Table 4: The average word count of each category of medical information in 
               Chinese and British antidepressant adverts  








Chinese ads British ads
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Table 4 shows that the content in relation to categories of dosage, precaution, drug 
interaction, adverse effects and overdose in British adverts significantly exceeds those 
in the Chinese. Interestingly, all of these categories focus on the use of antidepressants, 
and critical information concerning them, indicating the concepts of caution, danger 
and adverse effects. Chinese adverts clearly underrepresented such categories.  
 
The only category in which Chinese adverts use more words than British ones is 
contraindication. The average word count of this category is 67 in Chinese adverts, and 
15 in British ones. It will be interesting to see a comparison of representation in this 
category. Here, we extract two typical ones from each side: 
British adverts: 
1). Contra-indication: Hypersensitivity to Paroxetine. Use with MAOIs (refer to drug 
interactions).  
2). Contra-indications: Hypersensitivity to any component of the product.  
Chinese adverts: 
1). Translation: 
Contraindication: 1. Hyperactivity to Tianeptine or other components). 2. Children aged 
below 15 years. 3. Concomitant use with MAOIs. 4. Do not use Tianeptine within two 
weeks after MAOIs treatment. Patients who change treatment from Teaneptine to 
MAOIs only need to leave one day before starting MAOIs.  
2). Translation: 
Contraindication: Hyperactivity to Trazodone Hydrochloride. Patients with severe liver 
function impairment, severe Cardiac conditions, and mental disabilities should not use 
Tianeptine treatment.  
 
Clearly, in British adverts, the content in the category of contraindication is 
predominantly represented as “hypersensitivity to any components”, while in Chinese 
adverts, apart from the issue of hypersensitivity, general descriptions related to drug 
interaction and precaution are included. The word count information provided in Table 
4 indicates that British adverts describe the information of these two categories in a 
 14 
much more detailed way. Therefore, it is interesting to find out here that Chinese adverts 
tend to mix the information related to contraindication, drug interaction and precaution 
together and put them all in one category of contraindication, with oversimplified 
language. This forms another distinctive feature of Chinese antidepressant advertising.  
 
5.2 A Corpus-Assisted Critical Discourse Analysis of Chinese antidepressant adverts 
To discover the predominant ways of representing antidepressants in Chinese adverts, 
a special corpus is built for this research including all 424 advertisements that appear 
in the Chinese Journal of Psychiatry from 1996 to 2015, and the size of the corpus is 
73,719 words. To draw a comparison between Chinese and British texts, five British 
adverts have been randomly chosen, with a corpus word count of 3,842. Three of the 
main corpus research methodologies: frequency analysis, collocation analysis and 
keyword analysis, will be used in this study. 
 
5.2.1 Frequency analysis: information on use and dosage 
Using a frequency analysis, from two sets of wordlists extracted from the Chinese and 
British antidepressant advertisements, we can see the top 20 most frequent words in the 
two corpora:  
Table 5: Top 20 frequent words in Chinese and British antidepressants adverts 
Chinese advertisements British advertisements 
1. 焦虑 (anxiety)39 11. 法 (method) 1. Patients 11. Symptoms 
2. 治疗 (treatment, treat)40 12. 用 (using) 2. Day 12. Caution 
3. 抑郁症 (depression) 13. 不良 (adverse) 3. Mg 13. Seroquel 
4. 抑郁 (depressive) 14. 一 (one) 4. Dose 14. Anxiety 
5. 剂量 (dosage) 15. 患者 (patients) 5. Treatment 15. Daily 
6. 对 (for) 16. 品 (product) 6. Disorder 16. Vanlafaxin 
7. 本 (this) 17. 天 (day) 7. Use 17. Depressive 
8. 片 (tablets) 18. 次 (time) 8. Tablets 18. Recommended 
9.服用 (administration) 19. 症 (symptoms) 9. Xl 19. Severe 
10.反应 (effects) 20.过敏 (hypersensitivity) 10. increased 20. dosage 
                                                          
39 In presenting the research results generated from language software, only Chinese characters and their English 
translations are provided. For all the Chinese characters that are incorporated in the texts, both English 
translations and pinyin will be provided. 
40 In Chinese language, 治疗 can be used as both a noun (treatment) and a verb (to treat). 
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The top 20 words in Chinese adverts fall neatly into the following four categories of 
information: 
1) Indication：焦虑 (anxiety), 治疗 (treatment, treat), 抑郁症 (depression), 抑郁 
(depressive), 症 (symptoms) 
2) Dosage and administration: 剂量 (dosage), 片 (tablets), 服用 (administration), 法 
(method), 用 (using), 一 (one), 天 (day), 次 (time) 
3) Adverse effects: 不良 (adverse), 反应 (effects) 
4) Contraindication: 对 (for), 本 (this), 品 (product), 过敏 (hypersensitivity), 患者 
(patients) 
 
It is interesting to find that the anxiety (jiaolv, 焦虑) is the most frequent word in the 
Chinese corpus, with treatment/treat (zhiliao, 治疗) as the second. Examining the texts 
in which anxiety occurs shows that it is uniformly used in the category of indication 
with rare exceptions, to describe the symptom that antidepressants can treat.  
 
A more detailed analysis of treatment/treat (zhiliao, 治疗) in Chinese adverts shows 
that the following sentence is overwhelmingly used in the category of indication: (this 
product is used to) treat all types of depression (including mild, moderate and severe), 
depressive symptoms, generalized anxiety disorder. The dominant use of such a 
structure contributes to the high frequencies of words like anxiety (jiaolv, 焦虑), 
treatment/treat (zhiliao, 治疗), depression (yiyuzheng, 抑郁症), depressive (yiyu, 抑
郁), symptoms (zheng, 症). This indicates that in Chinese adverts, the category of 
indication has been over-generalized into two words/phrases: anxiety, and depressive 
symptoms, without pointing out important differences between brands of 
antidepressants and the different types of depression that they treat. Thus, 
antidepressants have been represented as a one-for-all medicine that doctors can 
prescribe for patients who have depressed feeling or a generalized condition of anxiety.  
 
By contrast, in British adverts, the description for usage of the antidepressant is much 
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more clear and concise:  
Use: Treatment of schizophrenia. Treatment of manic or major depressive episodes 
associated with bipolar disorder. Seroquel XL is effective in preventing relapse in 
stable schizophrenic patients who have been maintained on Seroquel XL.  
 
Here, the use of a particular brand of antidepressant is described in relation to specific 
types of depression with distinctive symptomatic features, providing more detailed 
information for prescribing doctors. 
 
To look into the category of dosage information, we directly searched the texts in which 
the most frequent words about dosage (see Table 5) occurred: dosage (jiliang, 剂量), 
and method (fa, 法), and using (yong, 用). Surprisingly, the short sentence “One tablet 
a day, convenient using method” (mei tian/ri yi pian, 每天/日一次, fu fa fang bian服
法方便) stands out as a predominant structure and there is hardly any further 
information about dosage. By contrast, we find detailed information provided in the 
British adverts, for example: 
Dosage: Adults: Depression: 20 mg a day recommended. If necessary increase 
dose in 10 mg increments to a maximum of 50 mg according to response. Obsessive 
compulsive disorder: 40 mg a day recommended. Starting dose 20 mg a day increased 
weekly in 10 mg increments. Maximum dose 60 mg a day. Panic disorder: 40 mg a day 
recommended. Starting dose 10 mg a day; dose increased weekly in 10 mg increments. 
Maximum dose 50 mg a day. Social anxiety disorder/social phobia: 20 mg a day 
recommended. Starting dose 20 mg per day. If no improvement after at least two weeks 
increase by 10mg per week up to a maximum of 50 mg/day according to response. 
Effective in 12 week placebo-controlled trials. Only limited evidence of efficacy after 
12 weeks of treatment. Post-traumatic stress disorder: 20 mg a day is recommended 
starting and maintenance dose. Some patients may benefit from dose increases in 10 
mg increments as required up to a maximum of 50 mg/day according to response. 
Effectiveness has not been evaluated beyond 12 weeks in placebo controlled trials.  
 
In this typical dosage information extracted from the British corpus, we find six words 
(emboldened in the above text) which enter the top 20 wordlist of the British corpus 
shown in table 5. It provides detailed information for different types of depression, such 
as general depression, obsessive compulsive disorder, panic disorder, social anxiety 
disorder/social phobia and post-traumatic stress disorder. It also includes the 
instruction based on patients’ response to their starting dose, such as if no improvement 
 17 
after two weeks increase by 10mg per week up to a maximum of 50 mg/day. Similarly, 
readers are reminded of the importance of continuous treatment after recovery, and the 
danger of abrupt discontinuation. It is therefore fair to conclude that in this comparison 
of Chinese and UK antidepressant adverts, the Chinese dosage and administration 
information has been heavily simplified, echoing the average word count analysis 
shown in Table 4. 
 
In this top 20 wordlist, we find two words不良 (adverse), and反应 (effects), but none 
of the rest of the words indicate the content of this category. Similarly, in the British 
wordlist, we do not find adverse effects, nor words that might be used to describe the 
actual side-effects of antidepressants. Therefore, the corpus research method of 
collocate analysis was used to investigate the features of the language describing the 
side-effects of antidepressants. 
 
5.2.2 Collocate analysis: adverse effects and contraindications 
In this section, we look at all the words that co-occur with adverse effects (buliang 
fanying, 不良反应) within 5 positions to the left and right.41 Wordsmith Tools (Scott, 
2008) enables the generation of a list of such words collocates based on their raw 
frequencies, called a collocation profile. The following table shows the top ten words 
in this profile: 
 
Table 6: Top collocates of不良反应 (adverse effects) in the Chinese corpus of 
                antidepressant advertisements 
 




1 不良(adverse) 不良反应 317 0 0 
2 反应(effects) 不良反应 315 4 311 
3 较(comparatively) 不良反应 59 27 32 
4 及(and) 不良反应 58 0 58 
5 常见(common) 不良反应 54 50 4 
                                                          
41 This decision is based on the concept of strength of relationship between a searched word and its collocates. 
Please refer to Wordsmith (Scott, 2008) “collocation display” for a more detailed explanation.  
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6 与(with) 不良反应 40 0 40 
7 包括(include) 不良反应 35 0 35 
8 因此(so) 不良反应 27 0 27 
9 详(detailed) 不良反应 24 0 24 
10 少(rare) 不良反应 24 4 20 
 
The lines in which adverse effects (buliang fanying, 不良反应) and these listed words 
co-occur represent the side-effects as comparatively rare. We find citations like “the 
common side-effects of antidepressants include very light stomach discomfort”, and 
“for detailed information in relation to adverse effects and precautions please refer to 




1. …has comparatively little influence on cytochrome oxidase, and the side-effects are 
comparatively rare.  
2. …is convenient to take and its dosage is easy to adjust. The toxins brought by the 
medicine are easy to be excreted. Besides, its side-effects are comparatively rare, and 
the safety range is relatively wide.  
3. Adverse effects include: very light stomach discomfort and nerve disorders.   
5. …is effective for long-term treatment with low relapse rate. It is also with light side-
effects, high drug tolerance and unique package design.  
6. …causes extremely rare drug interaction, and its side-effects are rare and light.] 
 
By contrast, British adverts adopt a universal way in displaying very clear and 
straightforward contents about adverse effects. Instead of looking into the collocation 
profile of side-effects, the following typical example provides a better picture: 
 
SIDE-EFFECTS: Nausea, headache, insomnia, somnolence, dry mouth, dizziness, 
constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, 
anxiety, impotence, abnormality of accommodation, vasodilation, vomiting, tremor, 
paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight 
gain, agitation, decreased libido, rise in blood pressure, postural hypotension, 
reversible increases in liver enzymes, slight increase in serum cholesterol, 
hyponatraemia. 
 
It is important to point out that the above displayed side-effects are equivalent to the 
 19 
information included in the medical instructions. Therefore, when we revisit the 
regulation for prescription drug advertising issued by the SAIC and SFDA: “Such 
contents…shall conform to the instructions approved by the food and drug 
administrative department of the State Council”, and “The publicity may not be 
conducted by exaggerating or maliciously hiding certain information…” we can assume 
that the implementation of such regulation needs to be improved in China.  
 
Lastly, in the category of contraindication, as the analysis in Section 3 shows, one of 
the distinctive features of the Chinese antidepressant adverts is that they try to mix the 
information related to contraindication, drug interaction and precaution under one 
category of contraindication and describe them in simplified terms. Therefore, we do 
not see any words related to drug interaction or precaution in the Chinese wordlist, and 
thus the significant collocates extracted for such low-frequency words are not revealing. 
However, when we look directly into the texts of adverts that include the content related 
to contraindication in Chinese adverts, we found that the following sentence is 
overwhelmingly used: 对本品过敏者及正在服用单胺氧化酶抑制剂的患者禁用本
品 (Not recommended in patients who have hypersensitivity to this product and patients 
taking MAOIs.)  This explains why words for (dui, 对), this (ben, 本), product (pin, 品), 
hypersensitivity (guomin, 过敏), patients (huanzhe, 患者) fall within the top 20 wordlist, 
and this over-simplified sentence has actually been used as the only information 
concerning the risks (negative side) of antidepressants.  
 
By contrast, in the British wordlist, words like patients, caution, severe, and 
recommended are very likely to occur in the categories of drug interaction and 
precaution. The word patients occurs as the most frequent word in the British corpus. 
Therefore, it is important to find out how British adverts construct patients, which might 
throw light on the content of the categories of contraindication, drug interaction and 
precaution. Using a Wordsmith “word cluster” function - an extended application of 
collocate analysis, the top ten 3-word clusters in the British corpus can be identified:    
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Table 7: The most frequent word clusters of patients in the British corpus of    
               antidepressant Advertisements 
 
Cluster Freq. Length 
IN PATIENTS WITH 9 3 
CAUTION IN PATIENTS 6 3 
IN PATIENTS TAKING 4 3 
HEPATICALLY-IMPAIRED PATIENTS TAKING 3 3 
WITH CAUTION IN 3 3 
USE WITH CAUTION 3 3 
IN THE ELDERLY 2 3 
INCREMENTS SOME PATIENTS 2 3 
MG INCREMENTS SOME 2 3 
MAY BENEFIT FROM 2 3 
 
As we see, of these ten 3-word clusters, five contain patients, with the first one as in 
patients with, and the second caution in patients. Another two frequent clusters 
containing caution are with caution in and use with caution. It is fair to assume that the 
frame use with caution in patients with/taking should form a repeated pattern. Therefore, 
all the lines that containing in patients were extracted, to ascertain whether this 
assumption is right. 
 
Table 8: Concordance lines of in patients in the British Corpus of Antidepressant 
               Adverts
 
N Concordance
20 patients taking warfarin. Potent CYP3A4 inhibitors or drug combinations in particular serotonergic drugs, lithium, clozapine or haloperidol in 
21 patients over 65 years with depressive episodes in the framework of to an effective dose. Efficacy and safety have not been evaluated in 
22 patients with congenital long QT syndrome, congestive heart failure, drugs known to prolong the QTc interval, especially in the elderly, in 
23 patients with increased risk factors for suicide at initiation of treatment, disorder: A maximum of two weeks supply should be considered in 
24 patients taking other CNS-active drugs in particular serotonergic drugs, caution in elderly or hepatically-impaired patients taking cimedidine, in 
25 patients with epilepsy; stop treatment if seizures develop. Driving and . Precautions History of mania. Cardiac conditions: caution. Caution in 
26 patients with a family history of QT prolongation, and in combination CYP3A4 such as azole antifungals and macrolide antibiotics. Caution in 
27 patients with myocardial infarction, unstable heart disease, renal or , patients aged below 18 years. PRECAUTIONS: Use with caution in 
28 patients taking other CNS-active drugs or in the elderly or or if they become or intend to become pregnant. Use with caution in 
29 patients with cardiovascular disease, cerebrovascular disease or other with quetiapine as compared to those treated with placebo. Caution in 
30 patients with established cardiac disease that may increase the risk of of aggression and psychomotor restlessness. Use with caution in 
31 patients with risk factors for the development of diabetes mellitus. . Appropriate clinical monitoring is advisable in diabetic patients and in 
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As predicted, we find 6 lines containing caution in patients with/taking. And it is 
obvious to see that the majority of these lines are used to refer to the precaution and 
drug interaction categories (with lines about in patients with for precaution, and in 
patients taking for drug interaction), with a small portion of the content being used in 
the category of dosage information (line 23). This content provides detailed information 
concerning patients’ medical conditions, such as patients with congenital long DT 
syndrome, epilepsy, myocardial infarction, or established cardiac disease. The concept 
of caution is continuously emphasised, keeping readers alert. This content is equivalent 
to that provided in the medical instructions accompanying antidepressants. By contrast, 
Chinese adverts remain silent in such areas. This echoes our analyses shown in Table 5, 
that only around 12 per cent of adverts include information related to precaution, 
around 10.4 per cent to drug interaction, and the contents in these two categories are 
usually over-simplified. 
 
Overall, the differences between Chinese and British adverts are significant. Firstly, 
most Chinese adverts cover the categories of information related to the use, dosage, 
side-effects and contraindications of antidepressants. British adverts, on the other hand, 
not only cover the above-mentioned categories, but use more space for the categories 
of precaution and drug interaction. Secondly, the content of every category in Chinese 
adverts is generally oversimplified, for example, with the use of antidepressants 
described as to treat depressive symptoms and anxiety, with the dosage information as 
once a day, with side-effects as very rare (light), and with contraindication as 
hypersensitivity to this product. British adverts, by contrast, provide a significantly 
more detailed picture for each category, especially in the dosage information. Lastly, 
British adverts have highlighted the concept of caution by providing large-scale 
detailed information in relation to precaution and drug interaction while Chinese 
adverts keep silent in this issue.  
 
5.2.3 Keyword analysis: changes over time 
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Using Wordsmith keyword analysis one can see even more clearly which aspects of 
antidepressants have been focused on, and which ones less talked about over time. As 
the British adverts have adopted a consistent way (in both structure and content) of 
displaying antidepressant information, we will mainly look at what categories of 
information Chinese adverts have emphasized from 1996 to 2015, and have they 
changed over time?  
 
Based on the analysis of the frequency changes of Chinese adverts and their related 
social contexts shown in Table 1, we divide the Chinese corpus into three time Phases: 
1996 to 2002, 2003 to 2008 and 2009 to 2015. The following table shows the three sets 
of keyword lists for the defined Phases; (the words given bold indicate the 
distinctiveness of each time Phase): 
Table 9: Distribution of keywords in the Chinese corpus of antidepressant adverts 


































怡 (Efextor XR) 
药 (medication) 
适应症 (indication) 
















胺  (amine) 
氧化酶 (oxidase) 




These three keyword lists overlap each other to a large extent, including a certain 
amount of common words such as treatment/treat, depression, anxiety, dosage, etc., 
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words indicating the chemical or brand names of antidepressants, such as Efextor XR 
(yinuosi, 怡诺思) and Zoloft (yulefu, 郁乐复), some distinctive phasal key words stand 
out, carrying important connotations relating to the development of Chinese 
antidepressant advertisements. For example, in the first Phase, two phasal key words 
are: effectiveness and effective, implying that from around the mid-1990s to the 
beginning of the 2000s, the basic theme of Chinese adverts is that antidepressants are 
effective in treating depressive symptoms, and such effectiveness is repeatedly 
emphasised. From the second Phase onwards, more formal and scientific names of the 
categories of information start to appear, such as indication (shiyingzheng, 适应症), 
and adverse effects, implying that Chinese adverts began to develop in a more scientific 
and objective way. In a similar way, in the third Phase, contraindication (jinyong, 禁
用) and hypersensitivity entered as new key words, indicating that Chinese adverts in 
the last ten years have begun to include information related to the contraindications of 
antidepressants, though these are oversimplified as “Not recommended for patients who 
have hypersensitivity to any components of the product”. At the same time, we found 
words detailed (xiang, 详), and medical instruction (shuomingshu, 说明书) enter this 
key word list, and an examination of these two words in the context of Chinese adverts 
indicates that they occur in the typical sentence: “For detailed information related to 
contraindication and adverse effects of this product, please refer to the medical 
instructions.” This implies that drug advertising regulations have been tightened to 
require the inclusion of the categories of contraindications and adverse effects, but the 
pharmaceutical companies have responded to this simply by adding a standard clause 
referring the reader to the medical instructions. 
 
6. Conclusion and Discussion 
 
On a linguistic level, Chinese adverts tend to use generic language to represent 
antidepressants as very effective, with rare side-effects, and as a convenient-to-use 
medication. In describing the use of antidepressants, they over-emphasize the 
symptomatic problems that antidepressants can treat, especially anxiety, and 
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depressiveness, catering to the localization and conceptualization of mental illness and 
antidepressants within Chinese culture. That is, Chinese people tend to somatize 
depression42 due to the social stigma attached to psychological or psychiatric conditions. 
The adverse effects of antidepressants have been largely represented in highly generic 
language such as very rare and extremely light. This leads to the unbalanced 
representation of the information in Chinese medical journals. The basic theme of 
caution, which is continuously reiterated in British adverts, does not exist in Chinese 
adverts, because the information related to the categories of drug interaction and 
precaution is largely omitted. Being exposed to such limited, inaccurate and unbalanced 
sources of information about antidepressants may lead doctors to inaccurately or over-
prescribe antidepressants.  
 
The findings of the discourse analysis of Chinese antidepressant advertisements reflect 
that, from the policy level, more nuanced Chinese regulatory laws related to the 
contents of prescription drug advertising need to be established. As addressed earlier, 
the current regulation related to the content of advertisements states that they shall 
conform to the instructions approved by the food and drug administrative department 
of the State Council. A recent development here is that in 2015, China’s Advertising 
Law saw its first amendment in two decades highlighting that: Drug and device 
advertisements must clearly state critical information about the products, such as 
contraindication and adverse effects; Drug and device advertisements must not contain 
absolute assurances or guarantees of the product’s safety43. This indicates that China 
has realized the necessity of including critical information in the advertisements. 
However, as our diachronic analysis of the keywords shows, pharmaceutical companies 
tend to use the sentence: Please refer to the medical instructions for detailed 
information related to adverse effects and contraindication. Therefore, to ensure that 
detailed and balanced information is provided, regulatory laws should further indicate 
that all the categories of information displayed in the instructions should be covered, 
                                                          
42 Kleinman 1982. 
43 Standing Committee of the NPC and SAIC 2015, article 16. 
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and the content in each category should reach a certain specified threshold of detail.  
 
In policy terms, to ensure the accessibility, reliability and balanced supply of 
information in medical advertisements, advertising law also needs to be effectively 
implemented and enforced. This clearly depends on a complex mix of coordinated 
action between many interest and stakeholder groups: government, regulatory 
authorities, medical organizations, pharmaceutical companies, media, public health 
service and others. Moreover, due to the large financial stakes involved and the complex 
financial and political relationships between these groups enforcing these laws can be 
very difficult. Complicating this, as our discourse analysis shows, Chinese 
advertisements describe the use of antidepressants as treating an inappropriately wide 
range of symptomatic problems, minimizing their side-effects. These problems are 
closely related to the cultural understanding of mental depression and antidepressants 
in China. Recognizing this, it is important to draw some of the conclusions in regards 
to debates around policy learning and transfer. In the area of antidepressant drug 
advertising, Chinese policy-makers must remember that: 
 They cannot simply copy an existing policy structure from another area/country 
and expect it to work in the same way. As our analysis demonstrates, there are 
too many interdependent factors for this to occur. 
 Policies always have social and cultural meanings. Mental health is one of the 
most socially and culturally difficult areas for societies to confront. Hence, this 
will continue to be a highly contested policy area. 
 Nevertheless, learning from other policy actors and contexts can be very useful. 
The limited two country comparison (China-UK) that was utilized in this article 
highlighted a number of weaknesses in the Chinese regulatory framework. This 
does not imply that copying UK regulation would necessarily solve Chinese 
policy issues. However, as a method of reflecting upon internal structures and 
strategies, sensitive and contextual international policy comparison is an 
excellent choice. 
 Lastly, this is a continual policy process. Medications, information technologies 
 26 
and advertising do not stand still. Though Chinese antidepressant policy could 
be seen to be ‘catching up’ with British regulation, this does not mean that it 
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